Invo Bioscience Stock Analysis

INVO -  USA Stock  

USD 1.01  0.08  7.34%

The big decline in price over the last few months for Invo Biosciencemay raise some interest from institutional investors. The stock closed today at a share price of 1.01 on 89,619 in trading volume. The company executives failed to add value to investors and position the firm supply of money to exploit market volatility in April. However, diversifying your holdings with Invo Bioscience or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.45. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Invo Bioscience partners.
Please see Risk vs Return Analysis.
  
Refresh
The Invo Bioscience stock analysis report makes it easy to digest most publicly released information about Invo Bioscience and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Invo Bioscience Stock analysis module also helps to analyze the Invo Bioscience price relationship with some important fundamental indicators such as market cap and management efficiency.

Invo Bioscience Stock Analysis Notes

About 16.0% of the company shares are owned by institutional investors. The book value of Invo Bioscience was currently reported as 0.25. The company recorded a loss per share of 1.09. Invo Bioscience had not issued any dividends in recent years. The entity had a split on the 9th of November 2020. INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. The company was founded in 2007 and is based in Sarasota, Florida. Invo Bioscience operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To learn more about Invo Bioscience call the company at 978 878 9505 or check out https://www.invobio.com.

Invo Bioscience Quarterly Cost of Revenue

64,961

Share

Invo Bioscience Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Invo Bioscience's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Invo Bioscience or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Invo Bioscience generated a negative expected return over the last 90 days
Invo Bioscience has high historical volatility and very poor performance
Invo Bioscience has some characteristics of a very speculative penny stock
Invo Bioscience has high likelihood to experience some financial distress in the next 2 years
Invo Bioscience was previously known as INVO BIOSCIENCE INC and was traded on NASDAQ Exchange under the symbol IVOB.
The company reported the previous year's revenue of 4.16 M. Net Loss for the year was (6.65 M) with profit before overhead, payroll, taxes, and interest of 4.03 M.
Invo Bioscience currently holds about 5.68 M in cash with (6.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47.
Invo Bioscience has a poor financial position based on the latest SEC disclosures
Latest headline from www.defenseworld.net: Invo Bioscience vs. Retractable Technologies Head-To-Head Analysis - Defense World

Invo Bioscience Upcoming and Recent Events

Earnings reports are used by Invo Bioscience to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Invo Bioscience previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report29th of March 2022
Next Financial Report16th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End29th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Invo Bioscience Largest EPS Surprises

Earnings surprises can significantly impact Invo Bioscience's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-16
2021-06-30-0.19-0.170.0210 
2022-05-16
2022-03-31-0.25-0.220.0312 
2021-11-15
2021-09-30-0.2-0.24-0.0420 
View All Earnings Estimates

Invo Bioscience SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Invo Bioscience prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Invo Bioscience investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Invo Bioscience specific information freely available to individual and institutional investors to make a timely investment decision.
16th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
31st of March 2022
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
View
22nd of February 2022
Unclassified Corporate Event
View
11th of February 2022
Unclassified Corporate Event
View
2nd of February 2022
Financial Statements and Exhibits. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
20th of January 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
6th of January 2022
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
2nd of December 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View

Invo Bioscience Thematic Classifications

In addition to having Invo Bioscience stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Medical Equipment IdeaMedical Equipment
USA Equities from Medical Equipment industry as classified by Fama & French

Invo Bioscience Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Invo Bioscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Invo Bioscience backward and forwards among themselves. Invo Bioscience's institutional investor refers to the entity that pools money to purchase Invo Bioscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Awm Investment Company IncCommon Shares1.2 M3.1 M
Vanguard Group IncCommon Shares356.7 K942 K
Geode Capital Management LlcCommon Shares87.2 K230 K
Connors Investor Services IncCommon Shares49 K129 K
Susquehanna International Group LlpCommon Shares31.8 K84 K
Citadel Advisors LlcCommon Shares25.6 K68 K
Blackrock IncCommon Shares25.1 K66 K
Simplex Trading LlcPut Options16.8 K44 K
Note, although Invo Bioscience's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Invo Bioscience Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 12.32 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Invo Bioscience's market, we take the total number of its shares issued and multiply it by Invo Bioscience's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Invo Bioscience Profitablity

Invo Bioscience's profitability indicators refer to fundamental financial ratios that showcase Invo Bioscience's ability to generate income relative to its revenue or operating costs. If, let's say, Invo Bioscience is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Invo Bioscience's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Invo Bioscience's profitability requires more research than a typical breakdown of Invo Bioscience's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (159.97) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (125.39) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -1.25.
Last ReportedProjected for 2022
Return on Average Assets(0.69) (0.74) 
Return on Average Equity(1.34) (1.37) 
Return on Invested Capital(1.90) (1.95) 
Return on Sales(1.29) (1.40) 

Management Efficiency

The entity has return on total asset (ROA) of (30.45) % which means that it has lost $30.45 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (101.96) %, meaning that it created substantial loss on money invested by shareholders. Invo Bioscience management efficiency ratios could be used to measure how well invo bioscience manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to slide to -0.74. The value of Return on Average Equity is estimated to slide to -1.37. Invo Bioscience Tangible Asset Value is quite stable at the moment as compared to the past year. The company's current Tangible Asset Value is estimated at 11.15 Million
Last ReportedProjected for 2022
Book Value per Share 0.69  0.74 
Enterprise Value over EBIT(7.00) (7.55) 
Enterprise Value over EBITDA(6.90) (7.45) 
Price to Book Value 5.34  5.11 
Tangible Assets Book Value per Share 0.97  0.82 
Enterprise Value36 M33.7 M
Tangible Asset Value10.3 M11.2 M

Technical Drivers

As of the 24th of May, Invo Bioscience retains the market risk adjusted performance of (0.72), and Risk Adjusted Performance of (0.28). Invo Bioscience technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Invo Bioscience, which can be compared to its competitors. Please check out Invo Bioscience information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Invo Bioscience is priced fairly, providing market reflects its last-minute price of 1.01 per share. Given that Invo Bioscience is a hitting penny stock territory we urge to closely look at its total risk alpha.

Invo Bioscience Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Mid-point over period is an average of Invo Bioscience highest and lowest values attained during the given period.
.

Invo Bioscience Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Invo Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Invo Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Invo Bioscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Invo Bioscience Predictive Daily Indicators

Invo Bioscience intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Invo Bioscience stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Invo Bioscience Forecast Models

Invo Bioscience time-series forecasting models is one of many Invo Bioscience's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Invo Bioscience's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Invo Bioscience Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Invo Bioscience stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Invo Bioscience shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Invo Bioscience. By using and applying Invo Bioscience Stock analysis, traders can create a robust methodology for identifying Invo Bioscience entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(1.25) (1.35) 
Gross Margin 0.96  0.96 
Profit Margin(1.60) (1.73) 
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. The company was founded in 2007 and is based in Sarasota, Florida. Invo Bioscience operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Current Invo Bioscience Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Invo Bioscience analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Invo Bioscience analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
5.0Buy2Odds
Invo Bioscience current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Invo Bioscience analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Invo Bioscience stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Invo Bioscience, talking to its executives and customers, or listening to Invo Bioscience conference calls.
Invo Bioscience Analyst Advice Details

Invo Bioscience Stock Analysis Indicators

Invo Bioscience stock analysis indicators help investors evaluate how Invo Bioscience stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Invo Bioscience shares will generate the highest return on investment. By understating and applying Invo Bioscience stock analysis, traders can identify Invo Bioscience position entry and exit signals to maximize returns.
Quick Ratio4.58
Fifty Two Week Low1.0500
Revenue Growth1,450.70%
Shares Short Prior Month89.71k
Average Daily Volume Last 10 Day57.83k
Average Daily Volume In Three Month38.16k
Shares Percent Shares Out0.48%
Gross Margins96.96%
Short Percent Of Float0.51%
Forward Price Earnings-2.33
Float Shares9.68M
Fifty Two Week High5.4280
Enterprise Value To Ebitda-2.83
Fifty Day Average1.9892
Two Hundred Day Average3.0677
Enterprise Value To Revenue3.53
Please see Risk vs Return Analysis. Note that the Invo Bioscience information on this page should be used as a complementary analysis to other Invo Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Invo Bioscience Stock analysis

When running Invo Bioscience price analysis, check to measure Invo Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Invo Bioscience is operating at the current time. Most of Invo Bioscience's value examination focuses on studying past and present price action to predict the probability of Invo Bioscience's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Invo Bioscience's price. Additionally, you may evaluate how the addition of Invo Bioscience to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Is Invo Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Invo Bioscience. If investors know Invo Bioscience will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Invo Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Invo Bioscience is measured differently than its book value, which is the value of Invo Bioscience that is recorded on the company's balance sheet. Investors also form their own opinion of Invo Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Invo Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Invo Bioscience's market value can be influenced by many factors that don't directly affect Invo Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Invo Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine Invo Bioscience value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Invo Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.